Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Mol Cancer Res. 2021 May 26;19(9):1510–1521. doi: 10.1158/1541-7786.MCR-21-0053

Fig. 4. Dose-response relationship between mean HED and clinical outcomes.

Fig. 4.

(a) Kaplan-Meier curve showing progression-free survival (PFS) stratifying patients by mean HED quartile (Q1 vs Q2/Q3 vs Q4). (b) Association between mean HED and maximum tumor shrinkage achieved in target lesions. The Spearman rank correlation test showed a negative correlation (rho: −0.24), but results were not statistically-significant. (c) Effect of mean HLA-I evolutionary divergence on hazard ratio for PFS across all possible cutpoints. The plot shows a negative relationship between mean HED and hazard ratio, indicating improved PFS as mean HED increases. (d) Subpopulation treatment effect pattern plot (STEPP) showing the 2-year progression-free probability across the mean HED range, higher HLA-I divergence was found to be associated with improved outcomes.